Bath Savings Trust Co Sells 909 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Bath Savings Trust Co reduced its stake in Thermo Fisher Scientific by 21.4%, holding 3,330 shares worth approximately $1.35 million after selling 909 shares in the second quarter.
• GAMMA Investing LLC significantly increased its position in the company by 60,610.9%, now owning over 2.4 million shares valued at around $1.2 billion.
• Analysts have set new price targets for Thermo Fisher Scientific, with Barclays raising their target from $490 to $550, indicating a positive outlook for the company's stock.

Bath Savings Trust Co decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 21.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,330 shares of the medical research company's stock after selling 909 shares during the quarter. Bath Savings Trust Co's holdings in Thermo Fisher Scientific were worth $1,350,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Mondrian Investment Partners LTD increased its holdings in shares of Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after acquiring an additional 127,357 shares during the last quarter. Advisors Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 6.7% during the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock worth $63,201,000 after acquiring an additional 7,967 shares during the last quarter. Foresight Group Ltd Liability Partnership increased its holdings in shares of Thermo Fisher Scientific by 3,242.7% during the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock worth $29,113,000 after acquiring an additional 56,747 shares during the last quarter. Ilmarinen Mutual Pension Insurance Co boosted its stake in Thermo Fisher Scientific by 5.3% in the 1st quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company's stock valued at $33,488,000 after purchasing an additional 3,400 shares during the period. Finally, GAMMA Investing LLC boosted its stake in Thermo Fisher Scientific by 22.0% in the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on TMO. UBS Group boosted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. HSBC restated a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Barclays upgraded Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $490.00 to $550.00 in a research note on Thursday, September 11th. Finally, Robert W. Baird upped their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Seventeen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average target price of $592.24.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded down $1.08 on Friday, hitting $480.02. 4,241,401 shares of the company's stock were exchanged, compared to its average volume of 1,433,914. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77. The stock has a market cap of $181.26 billion, a P/E ratio of 27.76, a price-to-earnings-growth ratio of 2.57 and a beta of 0.75. The company has a 50 day moving average of $472.01 and a 200 day moving average of $450.02.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.